Cancer in the cervix, which is the lower part of the uterus, is called cervical cancer. Its two primary types are squamous cells cancer and adenocarcinoma. 80% to 90%, i.e., a majority of cervical cancer cases fall under the former category. The latter is less common, constituting 10% to 20% of cases; however, the incidence of adenocarcinoma is rising predominantly in younger girls. Cervical cancer is a common type of cancer occurring in women across the world. A major cause is infection by human papillomavirus (HPV) which is found in 99% of cervical cancer cases.
Cervical cancer can be prevented via widespread immunization with the HPV vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones which cause genital warts. The Centers for Disease Control and Prevention (CDC) has recommended that the HPV vaccine be administered to girls and boys falling in the age group of 11 years to 12 years. Vaccination at an early stage of life, during teenage, is highly effective. In October 2016, the CDC updated the schedule of the HPV vaccination. It recommends that all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months.
The Cervical Cancer Therapeutics Market has witnessed significant growth in developed countries in last decade. Awareness initiatives taken by governments to educate women about early diagnostic test and treatment also increased. This helped in prevention of cervical cancer progression into aggressive or advanced stages. This restrained the cancer treatment market. Rise in prevalence, awareness, and advancement in treatment and various treatments available drive the cervical cancer therapeutics market. Readily available FDA-approved therapeutics such as ifosfamide (Ifex) and doxorubicin (Adriamycin) which are much cheaper contributed to growth of the global cervical cancer therapeutics market.
Ongoing research and presence of strong pipeline drugs are projected to boost the growth of the cervical cancer therapeutics market during the forecast period. The global surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at low cost. Most vaccines for cervical cancer are in their late stage of clinical development. Rise in incidence of cervical cancer has induced governments and non-profit organizations to take the initiative to create awareness regarding control and prevention of cervical cancer and HPV vaccinations. However, high cost of the vaccine and lack of awareness about HPV vaccination in developing countries act as the major restraints of the cervical cancer therapeutics market.
Request to View Brochure of Report -
The global cervical cancer therapeutics market can be segmented based on type of treatment, disease indication, and region. In terms of type of treatment, cervical cancer therapeutics market can be classified into cryotherapy, simple hysterectomy, cold knife conization, loop electrosurgical excision procedure (LEEP), laser surgery, cone biopsy, radical trachelectomy, radiation therapy (brachytherapy-BT and external beam therapy-EBT), chemotherapy, and targeted therapies such as bevacizumab, Pazopanib, and hormone therapy.
Comments
Post a Comment